Gavriel's story: helping future generations

12 Sep 2019, 11:28 a.m.

Seventeen year old Gavriel has a rare muscle condition called Duchenne Muscular Dystrophy (DMD). Together with his brother Joshua, aged eight, he is taking part in an innovative new clinical trial looking at how artificial intelligence (AI) can be used to track movement ability in boys with DMD.

Their mum Kerry tells their story:

“When Gavriel was around three he started waking up with severe leg cramps. Doctors didn’t know what it was and thought it might just be growth pains. Gavriel learnt to walk ok and met all his milestones but we decided to get it checked out and were referred to a developmental physiotherapist. She noticed that Gavriel had very large calf muscles which is a classic sign of Duchenne Muscular Dystrophy (DMD). We were referred for lots of tests and when they had the results the doctor called and asked us to come in to see her. I’ll never forget the meeting. It was a short time after that Gavriel was diagnosed with DMD. He was about four and back then the only treatment available was steroids. Other than that there was very little that could be done.”

Getting involved in research

“When he was a teenager Gavriel started to use his wheelchair more and more and eventually lost the ability to walk. This means he hasn’t been eligible for most of the new clinical research studies for DMD that have become available recently. Those studies all use a test that measures how far boys can walk in six minutes to see how effective a new treatment is at stopping the condition getting worse. But boys who are not able to walk like Gavriel can’t do that test so can’t take part in the new studies that would allow them to access to new treatments.

The AI bodysuit trial is really important because it means doctors can very sensitively and quickly see any declines in movement and scientists can look at how the disease progresses in individuals. The hope is that in time it could replace the six minute walk test and mean that all boys with DMD could be included in a trial. Gavriel’s brother Josh is also taking part as a healthy volunteer.

The new bodysuit trial is funded by the Duchenne Research Fund. The charity was set up by our family after Gavriel was diagnosed. We realised that there were pockets of research happening for DMD and we started fundraising within our local community to fund even more of this research. The charity has grown and grown and now helps fund groundbreaking research like this, bringing together experts from different fields.

Gavriel (right), his brother Josh, and mum Kerry

Helping future generations

“Gavriel is very driven and fierce. He goes to school every day by himself and loves horseriding and socialising. We always have a house full of his friends!

Our dream is that in 10-15 years time, when people get diagnosed with Duchenne they are not facing the same black hole that we did. We know we are still a long way off a cure but we want our family’s experience to be for something. We want to turn what potentially was a tragedy into an opportunity by knowing we are helping future generations with this vital research.”

New treatment for brain tumour approved after over 20 years of research

The first-ever targeted treatment for brain tumours in children has been approved for NHS patients, following decades of research by a Great Ormond Street consultant.

Kidney swap for GOSH patient who’s spent over 3,600 hours on dialysis

A five-year-old patient, who has spent almost 10% of her childhood on dialysis, has successfully had a transplant thanks to a kidney-swap scheme.

New cheek swab test helping to monitor children with rare heart condition

A cheap and simple test, being developed with funding from the British Heart Foundation (BHF), will allow quick and safe monitoring in children with arrhythmogenic cardiomyopathies (ACM).

New study finds that nasal cells protect against Covid-19 in children

New research shows that children are less likely than adults to develop severe COVID because cells in their nose are better at fighting off the virus.